At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
LOXO-305 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open Label, Two-part, Fixed-sequence Drug Interaction Study to Investigate the Effect of Strong CYP3A4 Inhibitor (Itraconazole) and CYP3A4 Inducer (Rifampin) on the Pharmacokinetics of LOXO 305 in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating LOXO-305, Itraconazole, and 1 other intervention for Healthy Volunteers. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The main purpose of this study is to learn about how itraconazole and rifampin affect LOXO-305 in healthy participants. Participation could last about 8 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartFeb 2020
Primary CompletionOct 2020
First PostedNov 2021
TodayJul 2026
First PostedNov 24, 2021
Enrollment StartFeb 12, 2020
Primary CompletionOct 30, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.6 years ago
Interventions
LOXO-305drug
Oral LOXO-305
Itraconazoledrug
Oral itraconazole
Rifampindrug
Oral rifampin